Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Oct 23, 2016 1:32pm
140 Views
Post# 25375810

RE:RE:RE:RE:Volumes

RE:RE:RE:RE:VolumesHi GV.

I was just trying to get my head around the total volume traded during the rise in share price so here is what I found;
  1. Note - The data are TSX trade only.
  2. The first volume jump was on Sept 13th at 59,680 shares.
  3. Then the share price started moving up on Sept 14th and peaked on Oct 5th at $2.47.
  4. The 5 day average volume was 116,176 prior to Sept 13th.
  5. From Sept 13th to Oct 11 the average 5 day volume was 445,912.
  6. The total volume traded from Sept 13 th Oct 11th was 1,783,646 shares.

If I recall the RVX float is about 120,000,000. I believe Eastern, NGN, Hepalink, Don control around 50% or more (roughly speaking).

So there may be approximately 60,000,000 shares in trading including all of the longs like me. So the trades from Sept 13th to Oct 11th represent approximately 2% of the "trading shares" including longs.

Anyway, this is a very rough tally. One thing for sure, we are not getting big daily trading volumes.

I have not incorporated the number of trades, size of trades and what brokers the trades were coming from so I have no idea the structure of the volume.

However, my guess is that the 1,783,646 shares have been bought by 1 or a few concentrated investors. And so my hypothesis is that somebody close enough to the inside learned something of significance in early September. I remember the run up before the Hepalink deal was announced.

Another thing that struck me (that is obvious to others) is that Hepalink has the rights to apabetalone in China, Taiwan, Macau, and the regions (whatever they are) and they have 13% of RVX shares. Therefore they serve to benefit from any successful compounds and deals RVX develops. And with their presence in the USA it could lead too very interesting possibilities.

Anyway, I'm just thinking out load and rambling here. November should be interesting.
GLTA
Toinv
Bullboard Posts